In that the FDA recently approved a combo study of Leronlimab and Bayer's Stivarga for treatment of mCRC, perhaps that means that Bayer is the undisclosed partner referenced by Pourhassan in today's Pro Active Investors interview.
Anyone has any guesses as to the name of the partner, and the terms of the non-binding offer sheet with such partner, referenced by Pourhassan in today's PAI interview?
LM
(0)
(0)
CytoDyn Inc (CYDY) Stock Research Links
The Lawmanstyle="color:red">The Lawman"color:red">The Lawman:red">The LawmanThe Lawmanspan>Lawmanawmanimg]